Skip to content

Kratom Use Disorder Management Using Clonidine and/or Buprenorphine

Kratom Use Disorder Management Using Clonidine and/or Buprenorphine

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05883358
Enrollment
50
Registered
2023-05-31
Start date
2018-07-02
Completion date
2025-12-31
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Withdrawal Syndrome

Keywords

Kratom

Brief summary

Kratom is used for stimulant, analgesic, anxiolytic, and sedative effects. There is inadequate knowledge about Kratom addiction. Kratom withdrawal may be treated like opioid withdrawal. Prospective observational crossover study of consenting adults who are undergoing Kratom withdrawal management. On alternate weeks, each patient receives treatment using Buprenorphine 5cmg/hr patch; or Clonidine tablet 0.1mg 4hourly; or combined Clonidine tablet 0.1mg 4hourly + Buprenorphine 5cmg/hr patch. Each patient will undergo treatment for 12 weeks. Patients will use Subjective Opiate Withdrawal Scale (SOWS) to collect data on daily basis. SOWS is a patient-administered tool that is used to record the severity and presence of opiate withdrawal. The physician will also use Clinical Opiate Withdrawal Scale (COWS) to collect data on weekly basis. COWS is a clinician-administered tool that is used to record the signs of opiate withdrawal. A change in the COWS and SOWS scores by 6-points is considered significant.

Detailed description

Kratom herb is used for stimulant, analgesic, anxiolytic, and sedative effects. There is inadequate knowledge about Kratom dependence and withdrawal therapy. Kratom withdrawal may be treated with similar therapy for opioid withdrawal. This is a prospective observational crossover study of consenting adult patients who are undergoing Kratom withdrawal management. On alternate weeks, each patient receives rotational treatment using Buprenorphine 5cmg/hr patch; or Clonidine tablet 0.1mg 4hourly; or combined Clonidine tablet 0.1mg 4hourly + Buprenorphine 5cmg/hr patch. Each patient will undergo Kratom withdrawal treatment for 12 continuous weeks. The patient will use the Subjective Opiate Withdrawal Scale (SOWS), a special validated scale, to collect data on daily basis. The SOWS is a patient-administered tool that is used to record the severity and presence of opiate withdrawal symptoms. In addition, the physician will use the Clinical Opiate Withdrawal Scale (COWS), a special validated scale, to collect data on weekly basis. The COWS is a clinician-administered tool that is used to record the symptoms and signs of opiate withdrawal or substance abuse disorder. A change in the COWS and SOWS scores by 6-points is considered significant. Data analyzed with IBM® SPSS® Statistics 25 (IBM Corp, Armonk, NY); using Student's t-test, ANOVA, Pearson Chi-square test, and regression analysis. P-value \<0.05 is considered significant.

Interventions

DRUGClonidine, Buprenorphine

Each patient receives rotational treatment using Buprenorphine 5cmg/hr patch; or Clonidine tablet 0.1mg 4hourly; or combined Clonidine tablet 0.1mg 4hourly + Buprenorphine 5cmg/hr patch.

Sponsors

Salem Anaesthesia Pain Clinic
Lead SponsorOTHER

Study design

Observational model
CASE_CROSSOVER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to 99 Years
Healthy volunteers
Yes

Inclusion criteria

* adult patients * Kratom dependence * Kratom withdrawal syndrome * Kratom withdrawal therapy * good treatment compliance * reliable Subjective Opiate Withdrawal Scale (SOWS) diary * reliable Clinical Opiate Withdrawal Scale (COWS) diary * informed consent for diary review * consent for clinical record quality assurance review

Exclusion criteria

* poor treatment compliance * cognitive disorder * inability to provide consent * major neuropsychiatric disorder * unreliable diary * cannabis use * excessive alcohol intake * previous adverse/allergic reactions to clonidine * previous adverse/allergic reactions to buprenorphine

Design outcomes

Primary

MeasureTime frameDescription
Clinical Opiate Withdrawal Score12 weeksClinical Opiate Withdrawal Score on a scale of 5 to 36; low scores indicate mild withdrawal, high scores indicate severe withdrawal

Countries

Canada

Contacts

Primary ContactOlu Bamgbade, MD,FRCPC
salem.painclinic@gmail.com17786286600

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026